---
nav_exclude: true
layout: default
title: "Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023"
source_url: "https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=733556"
source_layer: us_cdc_mmwr
category: surveillance_summary
date: 2023-02-02
confidence: 中
mmwr_volume: ""
mmwr_issue: ""
---

## 摘要

This report describes how a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2-4 monovalent vaccine doses.

## 詳細內容

This report describes how a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2-4 monovalent vaccine doses.

## 關鍵發現

(需要透過 WebFetch 補充或人工審核來提取關鍵發現)

---
*萃取時間: 2026-02-05T15:11:29Z*
*資料來源: CDC MMWR*
